Clinical characteristics of Crohn’s disease (CD) patients
| CD patients in remission (rCD, n = 20) | CD patients on infliximab (aCD, n = 21) | CD patients on iv corticosteroids (aCD, n = 9) | |
|---|---|---|---|
| rCD, Crohn’s disease in clinical remission; aCD, active Crohn’s disease; upper GI, upper gastrointestinal tract; EIM, extraintestinal manifestations; 5-ASA, 5 aminosalicylates; indications for infliximab (lum/fistul), luminal or fistulising disease; schedule of infliximab infusion (1 inf/3 inf), single or three dose regimen infusions; CRP, C reactive protein. | |||
| Male sex | 11 | 12 | 3 |
| Disease duration (y) | 9.7 (7.7) | 9.9 (7.7) | 6.6 (9.3) |
| Age (y) at diagnosis | 32.2 (14.3) | 26.5 (9.4) | 33.4 (12) |
| A1 | 15 | 18 | 7 |
| A2 | 5 | 3 | 2 |
| Disease location | |||
| Ileum only (L1) | 7 | 3 | 1 |
| Colon only (L2) | 5 | 9 | 5 |
| Ileum and colon (L3) | 7 | 5 | 3 |
| Upper GI (L4) | 1 | 4 | 0 |
| Disease type | |||
| Non-strict, non-penetr (B1) | 4 | 10 | 3 |
| Stricturing (B2) | 12 | 2 | 2 |
| Penetrating (B3) | 4 | 9 | 4 |
| EIM | 2 | 7 | 4 |
| Medications | |||
| 5-ASA | 14 | 9 | 6 |
| Prednisone | – | 8 | – |
| Methotrexate | – | 0 | 2 |
| Azathioprine | – | 12 | 1 |
| Budesonide | – | 7 | 1 |
| Infliximab | |||
| Indications (lum/fistul) | – | 15/6 | – |
| Schedule (1inf/3inf) | – | 6/15 | – |
| CRP (mg/dl) | 0.5 (0.1–0.5) | 4.275 (0.3–21.9) | 5 (0.8–47.9) |